Vol. 5 No. 7 (2025)
Reimbursement Recommendations

Fidaxomicin

decorative image of the issue cover

Published July 28, 2025

Key Messages

  • The Formulary Management Expert Committee (FMEC) recommends that fidaxomicin be reimbursed for the treatment of Clostridioides difficile infection (CDI) in adult patients who have an initial episode or first recurrence of CDI and are at high risk for recurrence or are allergic to vancomycin, provided certain conditions are met.
  • Fidaxomicin should be covered for the treatment of CDI for adult patients who have an initial episode or first recurrence of CDI and are at high risk for recurrence or are allergic to vancomycin.
  • Based on the Canada’s Drug Agency (CDA-AMC) assessment of the health economic evidence, fidaxomicin may not represent good value to the health care system at the public list price. A price reduction may therefore be required.